Heart Failure

The AJMC® Heart Failure compendium is a comprehensive resource for clinical news and expert insights for the chronic condition in which the heart doesn't pump enough blood due to damaged heart muscle.

Latest News

Doctor writing prescription | Image credit: 18percentgrey – stock.adobe.com
SGLT2i Prescriptions for Heart Failure Are Rising, but Vary Across US

November 18th 2024

Of the 518 hospitals that had at least 10 eligible discharges, only 11 of them prescribed SGLT2 inhibitors to more than half of their patients.

Liver and stethoscope | Image credit: filins – stock.adobe.com
Liver Fibrosis Scores May Hint at Heart Failure Risk

November 13th 2024

Man having heart attack | Image credit: JU.STOCKER – stock.adobe.com
β-Blockers May Raise Depression Risk for Heart Attack Survivors Without Heart Failure

November 13th 2024

Doctor holding stethoscope to red heart | Image credit: lenets_tan – stock.adobe.com
How the Clinical Trial Gender Gap Affects Women’s Heart Care

October 18th 2024

Woman at heart doctor | Image credit: Seventyfour – stock.adobe.com
Why Are We Still Seeing Gaps in Women’s Heart Care?

October 15th 2024

Heart Failure Clinical and Economic Burden

An in-depth discussion on the clinical and economic burden of treatment for patients with heart failure, with special consideration to progressive disease.

John McMurray screenshot
Continuing Medical Education
View All
November 21st 2024

Advances and Best Practices for Managed Care Pharmacists in the Treatment of Heart Failure with Preserved Ejection Fraction

1.0 Credits / Cardiology
November 21st 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
November 21st 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

Heart and stethoscope
November 10th 2021

Mortality Increase Seen in Patients With Heart Failure, Hypercapnia

Maggie L. Shaw
Outcomes of in-hospital mortality, 7-day mortality, and emergency department length of stay were investigated among a cohort of patients with acute heart failure and hypercapnia, or excessive levels of CO2 in the blood.
Heart function graphic
November 2nd 2021

Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI

Maggie L. Shaw
Individuals with a history of acute myocardial infarction (AMI), or heart attack, may benefit on several fronts following early administration of the neprilysin inhibitor/angiotensin receptor blocker sacubitril/valsartan.
heart
October 29th 2021

Social Vulnerability Linked to Premature Cardiovascular Deaths

Laura Joszt, MA
The counties in the United States with more social vulnerabilities had higher premature mortality related to cardiovascular diseases, such as heart disease, stroke, high blood pressure, and heart failure.
Picture of a thin and an obese body
October 27th 2021

Obesity Shown to Adversely Influence Heart Health Prior to Symptom Onset

Maggie L. Shaw
For 3 categories of evaluation, elevated cardiac troponin I levels most influenced the development of myocardial injury among persons at higher lifetime weight totals.
white pills coming out of bottle
October 13th 2021

Older Adults Should Not Take Aspirin to Prevent Heart Disease, USPSTF Recommends

Hayden E. Klein
The task force determined that potential harms of adults aged 60 and older using aspirin for prevention outweighed the benefits.
SGLT2 Inhibitors, GLP-1 RAs Featured in Prevention Guidelines
October 4th 2021

SGLT2 Inhibitors, GLP-1 RAs Featured in Prevention Guidelines

Mary Caffrey
The prevention document, released during ESC Congress 2021, marked the first update of this section of the guidelines in 8 years. It featured changes that reflect the arrival of a pair of drug classes with proven benefits in CV outcomes but that experts say are underutilized.
Blood pressure cuff
October 3rd 2021

Higher Odds of Hypertension Seen in Older Women, Younger Men

Hayden E. Klein
New research presented at the AHA Hypertension Scientific Sessions 2021 showed that men aged 20 to 49 years and women 70 and older both had a greater risk of hypertension.
Deepak L. Bhatt, MD, MPH, Harvard Medical School
October 1st 2021

Dr Deepak L. Bhatt: There Is a Lot of Excitement for HFpEF Right Now

In an interview for ESC Congress 2021, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, describes the treatment outlook for patients with heart failure with preserved ejection fraction (HFpEF).
Running figure with heart rate monitor
September 26th 2021

HIIT Improves Cardiorespiratory Fitness More Than Low-Intensity Exercise, Review Says

Hayden E. Klein
For patients with heart failure and cardiovascular disease, high intensity interval training has a greater positive effect on cardiorespiratory fitness than moderate intensity continuous training.
Remove Race From Equation Used to Assess Kidney Function, Researchers Say
September 23rd 2021

Remove Race From Equation Used to Assess Kidney Function, Researchers Say

Allison Inserro
Long-awaited reports released Thursday call for eliminating race in estimated glomerular filtration rate equations and point to alternatives in an effort to eliminate disparities in chronic kidney disease.
Stefan Anker, MD, PhD, FESC, Charité Campus Virchow Clinic, Berlin, Germany
September 21st 2021

Dr Stefan Anker: Patients With HFpEF Deserve a New Treatment

Maggie L. Shaw
With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction (HFpEF) is possible, said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study.
Site Logo
September 17th 2021

Diagnosis Patterns and Stress Testing Trends After Implementing High-Sensitivity Troponin Assay

Raymond Y. Yeow, MD Henry Han, MD James Henderson, PhD Katie Grzyb, MHSA, BSE Matthew Johnson, MS, MHSA Emily R. Dibble, BA Ashwin Gupta, MD Donald Giacherio, PhD James Froehlich, MD, MPH David Somand, MD Scott A. Flanders, MD Geoffrey D. Barnes, MD, MSc
This study found that switching from a conventional troponin assay to a high-sensitivity troponin assay resulted in changes to diagnosis patterns and stress testing trends.
Mom's Meals home delivery truck
September 16th 2021

Mom’s Meals Launches Pilot Program for California Health Plan Members With Heart Failure

Hayden E. Klein
The 6-month program provides nutrition education, healthy food and recipes, and home visits.
Entresto image
September 15th 2021

Lower Rehospitalization, Mortality Seen From Sacubitril/Valsartan Use for HFrEF

Maggie L. Shaw
Entresto (sacubitril/valsartan) was first approved for use in heart failure with reduced ejection fraction (HFrEF) in 2015.
heart graphic
September 13th 2021

Panel Outlines Updates on HF Treatment Developments, Recommendations for Guidelines

Gianna Melillo
In a panel at the 5th annual Heart in Diabetes Conference, John McMurray, MD, and Javed Butler, MD, highlighted recent pharmacological developments in heart failure (HF) and offered insights on overlooked areas in the field.
ESC Congress 2021: Solutions for Gender-Based Gap in Cardiovascular Disease Diagnosis
September 10th 2021

ESC Congress 2021: Solutions for Gender-Based Gap in Cardiovascular Disease Diagnosis

Hayden E. Klein
The Lancet commission aimed to connect stakeholders, raise global awareness of these inequities and disparities, and encourage future research.
Javed Butler, MD, MPH, MBA, University of Mississippi
September 7th 2021

Dr Javed Butler Discusses the Possibility of HFpEF Combination Treatment

Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), noted Javed Butler, MD, MPH, MBA, of the University of Mississippi.
Rudolf De Boer, Md, PhD, University Medical Center Groningen, the Netherlands
September 4th 2021

Dr Rudolf de Boer on SGLT2 Inhibitor Success Across Disease States

Maggie L. Shaw
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to both lower blood pressure and promote weight loss, and they act rather subtly, stated Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.
Blood pressure cuff
September 2nd 2021

STEP Trial Findings Build on SPRINT Results, With a Twist

Maggie L. Shaw
STEP findings build on those from the SPRINT trial, seemingly confirming that intensive treatment for hypertension can reduce the risk of serious adverse cardiovascular (CV) outcomes. However, there was no significant benefit toward risk for all-cause and CV-related mortality.
Older patient with physician
August 26th 2021

Better Screening Efforts Needed for Patients With T2MI, Heart Failure

Maggie L. Shaw
Although there is an established link between type 2 myocardial infarction (T2MI) and elevated rates of cardiovascular events, less is known about the connection between T2MI and heart failure—which this new study investigated.
Clinical Diversity of Cardiac Fibrosis, Treatment Effects Need More Study, Researchers Say
August 24th 2021

Clinical Diversity of Cardiac Fibrosis, Treatment Effects Need More Study, Researchers Say

Hayden E. Klein
Because cardiac fibrosis can develop under very diverse etiological circumstances, it is extremely heterogeneous.
Picture of heart and kidneys
August 20th 2021

Disconnect Between Heart, Kidneys Negatively Affects Heart Failure Outcomes

Maggie L. Shaw
Comorbid cardiac dysfunction and intrarenal venous congestion were shown in this new study to have a negative correlation with survival outcomes among individuals with all levels of heart failure.
Gender, Cancer, Diabetes Among Predictors of Mortality for Patients With HFpEF
August 18th 2021

Gender, Cancer, Diabetes Among Predictors of Mortality for Patients With HFpEF

Hayden E. Klein
Event-free survival rates were higher in women compared with men for all-cause mortality and first heart failure hospitalization.
pregnant
August 13th 2021

Gestational Diabetes Tied to Future Heart Failure in Study

AJMC Staff
The authors called for screening women for diabetes during pregnancy.
Parasite
August 6th 2021

History of Malaria May Indicate Greater Risk of Heart Failure

Hayden E. Klein
Individuals with a history of Plasmodium falciparum protozoan parasitic infection had a significantly increased long-term risk of developing heart failure but not myocardial infarction or cardiovascular or all-cause death.
Mariana Garcia, MD, Emory University
August 3rd 2021

Dr Mariana Garcia: We Cannot Overlook the Influence of Psychological Distress on Our Patients

Maggie L. Shaw
The pandemic has exacerbated not only cardiovascular care, but also the mental health of patients, noted Mariana Garcia, MD, cardiology fellow in the Academic Clinical Investigator Pathway at Emory University and member of T32, Multidisciplinary Research Training to Reduce Inequalities in Cardiovascular Health (METRIC).
Management of Obesity in Heart Patients Needs More Attention, Study Finds
July 28th 2021

Management of Obesity in Heart Patients Needs More Attention, Study Finds

Hayden E. Klein
The study found that more than a third of patients who were obese said they did not receive advice on physical activity or nutrition in order to lose weight, and nearly 1 in 5 said they were not even told they were overweight.
Clyde W. Yancy, MD, MSc, Northwestern
July 27th 2021

Dr Clyde Yancy: We Must Continue to Explore Why SGLT2 Inhibitors Are Effective in HF

Maggie L. Shaw
We do not yet know the exact mechanism of action of sodium glucose co-transporter-2 (SGLT2) inhibitors in heart failure (HF), but there are many exciting pssibilities, stated Clyde W. Yancy, MD, MSc, of Northwestern University’s Feinberg School of Medicine.
Mikhail N. Kosiborod, MD, Saint Luke's Health System
July 20th 2021

Dr Mikhail N. Kosiborod: DARE-19 Results Do Not Support SGLT2 Treatment Discontinuation

Maggie L. Shaw
Patients should continue to be monitored while on treatment with SGLT2 inhibitors if they are being treated for comorbid type 2 diabetes and heart failure, emphasized Mikhail N. Kosiborod, MD, cardiologist, vice president of Research at Saint Luke's Health System.
Pilot Suggests Additional Benefits of Entresto in Patients With HFrEF
July 17th 2021

Pilot Suggests Additional Benefits of Entresto in Patients With HFrEF

Mary Caffrey
When the sympathetic nervous system is unregulated, it can lead to high blood pressure and elevated heart rate.
<1
...
456789101112
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo